Brentuximab vedotin - Seattle Genetics/Takeda

Drug Profile

Brentuximab vedotin - Seattle Genetics/Takeda

Alternative Names: Adcetris; Anti-CD30-MMAE; Anti-CD30-monoclonal-antibody-cAC10-auristatin-E-conjugate; Auristatin-E-anti-CD30-monoclonal-antibody-cAC10-conjugate; cAC10-vcMMAE; MMAE-anti-CD30; SGN-35

Latest Information Update: 17 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Seattle Genetics; Stanford University
  • Developer Bristol-Myers Squibb; Celgene Corporation; Dana-Farber Cancer Institute; Fondazione Italiana Linfomi; Fox Chase Cancer Center; Immune Tolerance Network; Lymphoma Academic Research Organisation; Massachusetts General Hospital; National Cancer Institute (USA); National Institute of Allergy and Infectious Diseases; Seattle Genetics; Stanford University; Takeda; Takeda Oncology; UNC Lineberger Comprehensive Cancer Center
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hodgkin's disease; Non-Hodgkin's lymphoma; Anaplastic large cell lymphoma; Peripheral T-cell lymphoma; Cutaneous T cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Anaplastic large cell lymphoma; Cutaneous T cell lymphoma; Hodgkin's disease; Mycosis fungoides
  • Preregistration T cell lymphoma
  • Phase II Adult T-cell leukaemia-lymphoma; Diffuse large B cell lymphoma; Germ cell and embryonal neoplasms; Mastocytosis; Mesothelioma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; Sezary syndrome
  • Phase I/II Diffuse scleroderma
  • Phase I Graft-versus-host disease
  • Discontinued Leukaemia; Multiple myeloma; Solid tumours; Systemic lupus erythematosus

Most Recent Events

  • 05 Nov 2018 Preregistration for T-cell lymphoma (Combination therapy, First-line therapy) in USA (IV)
  • 05 Nov 2018 Seattle Genetics completes the phase III ECHELON-1 trial in Hodgkin's lymphoma (First line therapy)
  • 05 Nov 2018 Seattle Genetics completes the phase III ECHELON-2 trial in peripheral T-cell lymphomas (Combination therapy, First line therapy)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top